Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Format: Artigo
Jezik:Inglês
Izdano: NIHR Journals Library 2010-01-01
Serija:Health Technology Assessment
Teme:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Online pristup:https://doi.org/10.3310/hta14020
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items